Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacy, Central South University, Changsha, China.
Front Immunol. 2021 Feb 2;11:586760. doi: 10.3389/fimmu.2020.586760. eCollection 2020.
Cancer is an important threat to public health because of its high morbidity and mortality. In recent decades, immune checkpoint inhibitors (ICIs) have ushered a new therapeutic era in clinical oncology. The rapid development of immune checkpoint therapy is due to its inspiring clinical efficacy in a group of cancer types. Metformin, an effective agent for the management of type 2 diabetes mellitus (T2DM), has shown beneficial effects on cancer prevention and cancer treatment. Emerging studies have suggested that metformin in combination with ICI treatment could improve the anticancer effects of ICIs. Hence, we conducted a review to summarize the effects of metformin on ICI therapy. We also review the pleiotropic mechanisms of metformin combined with ICIs in cancer therapy, including its direct and indirect effects on the host immune system.
癌症因其高发病率和死亡率，是对公众健康的重要威胁。近几十年来，免疫检查点抑制剂（ICIs）在临床肿瘤学中开创了一个新的治疗时代。免疫检查点治疗的快速发展归因于其在一系列癌症类型中令人鼓舞的临床疗效。二甲双胍是治疗 2 型糖尿病（T2DM）的有效药物，它在癌症预防和治疗方面显示出有益的效果。新出现的研究表明，二甲双胍与 ICI 治疗联合使用可以提高 ICI 的抗癌效果。因此，我们进行了一项综述，以总结二甲双胍对 ICI 治疗的影响。我们还回顾了二甲双胍联合 ICI 在癌症治疗中的多效机制，包括其对宿主免疫系统的直接和间接影响。
